Segall Bryant & Hamill Boosts Stake in Cytokinetics

Institutional investor increases position in biopharmaceutical company by over 116%

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Segall Bryant & Hamill LLC, an institutional investor, has increased its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 116.1% during the third quarter, according to a recent SEC filing. The firm now owns 181,050 shares of the biopharmaceutical company's stock, worth approximately $9.95 million.

Why it matters

Cytokinetics is a late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function. The significant increase in Segall Bryant & Hamill's position suggests the institutional investor sees strong potential in the company's pipeline and future prospects.

The details

According to the 13F filing, Segall Bryant & Hamill purchased an additional 97,280 shares of Cytokinetics during the third quarter, bringing its total position to 181,050 shares. This represents approximately 0.15% of the company's outstanding shares. The institutional investor cited Cytokinetics' promising drug candidates and growth potential as reasons for the increased investment.

  • Segall Bryant & Hamill increased its position in Cytokinetics during the third quarter of 2026.

The players

Segall Bryant & Hamill LLC

An institutional investment firm that manages assets for clients.

Cytokinetics, Incorporated

A late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function.

Got photos? Submit your photos here. ›

The takeaway

Segall Bryant & Hamill's significant increase in its Cytokinetics position suggests the institutional investor sees strong potential in the company's pipeline and future prospects, underscoring the growing investor interest in the biopharmaceutical sector.